Plus Therapeutics Secures Medicare Enrollment for CNSide Diagnostic
Event summary
- Plus Therapeutics' subsidiary CNSide Diagnostics received Medicare enrollment approval on May 7, 2026.
- The approval enables billing for the CNSide® CSF Assay Platform under Medicare Fee-For-Service.
- CNSide Diagnostics aims to expand coverage to Medicare Advantage plans and Medicaid.
- The company targets 150 million+ covered lives by the end of 2026.
The big picture
The Medicare enrollment approval is a critical step in Plus Therapeutics' commercialization strategy, enabling access to approximately half of the U.S. Medicare population. This milestone strengthens the company's pathway to broader patient access, adoption, and revenue growth, particularly for patients with leptomeningeal metastases where conventional diagnostic methods often fall short. The approval also positions CNSide Diagnostics to pursue coverage with major Medicare Advantage plans and Medicaid, further expanding its market reach.
What we're watching
- Reimbursement Momentum
- Whether CNSide Diagnostics can secure formal coverage determinations from Medicare Administrative Contractors (MACs) to ensure sustained reimbursement.
- Pricing Determination
- The establishment of a payment rate for the new CPT code 0640U, effective July 1, 2026, and its impact on revenue.
- Commercial Expansion
- The pace at which CNSide Diagnostics can execute national and regional payer contracts to reach the goal of 150 million+ covered lives.
Related topics